Incorporating Assessments of Sequence-Dependence in Developmental Studies of Combination Chemotherapy Regimens Containing New Agents and Platinum Compounds

摘要: The evaluation of combination chemotherapy regimens that incorporate new drugs has been accepted as the next rationale step in development cytotoxic agents following completion phase I and early II trials. Before incorporating into regimens, agent should have demonstrated a sufficient level antitumor activity relevant tumor types. In addition, adequate preclinical clinical information about optimal scheduling be available. New are often combined with platinum compounds, such cisplatin carboplatin, if possess ovarian, non-small small cell lung, bladder, germ carcinomas, well other malignancies which compounds mainstay therapy.